COMPANY

NKGEN Biotech

HQ: Santa Ana, CA source · nkgenbiotech.com ↗ · West Coast

1 open job · last seen Oct 23, 2026 · 9 sources

NKGen Biotech is a clinical-stage biotechnology company. From company website Source · Oct 13, 2026

Keywords: biotechnology Alzheimer Disease Moderate Alzheimer Disease Pathologically Confirmed Cancer Refractory to Conventional Therapy Neuro-Degenerative Disease Squamous Cell Carcinoma of Head and Neck Non-Small-Cell Lung Carcinoma Colorectal Neoplasms HER2-positive Breast Cancer HER2-positive Gastric Cancer HER-2 Protein Overexpression Esophageal Cancer Ovarian Cancer Endometrium Cancer Bladder Cancer Pancreatic Cancer Colorectal Cancer Non Small Cell Lung Cancer EGF-R Positive Non-Small Cell Lung Cancer Head and Neck Squamous Cell Carcinoma Triple Negative Breast Cancer Cervical Cancer Sarcoma Plaque Psoriasis SNK01 SNK02 AFM24 Study Product: SNK01

Profile checked Oct 10, 2026

1Open jobs 8Trials (company is sponsor)

Hiring

Title	Location (from posting)	Employer posted	First seen
Analyst II	Santa Ana, CA, Santa Ana, CA, US	Sep 1, 2026	Oct 11, 2026

See all 1 job

Raises and deals from press releases

Raise Undisclosed round · $5M · announced Apr 11, 2024 Company release ↗
Source quote
- Apr 11, 2024 · Company release ↗
  “(Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer cell therapeutics, today announced that it has closed $5 million in second lien convertible loan”

Raises announced in these releases: $5M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Jul 17, 2025 Partnership Partnership / licensing announced Jul 17, 2025. Source: SEC filing. source ↗
Jun 30, 2025 Trial start Phase 2: Open-Label Extension Protocol to SNK01-AD01 Study source ↗
Apr 11, 2024 Raise Undisclosed round · $5M source ↗
Nov 21, 2023 Trial start Phase 1/Phase 2: Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease source ↗
Aug 23, 2023 Trial start Phase 1: Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy source ↗
Nov 3, 2021 Trial start Phase 1/Phase 2: Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers source ↗
Jan 6, 2021 Trial start Phase 1: Safety of SNK01 in Subjects With Alzheimer's Disease (ASK-AD) source ↗
Jul 18, 2019 Trial start Phase 1: Autologous Natural Killer Cells in Subjects With Plaque Psoriasis source ↗
Jul 15, 2019 Trial start Phase 1: Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy source ↗
2021-03 Trial start Phase 1/Phase 2: Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers source ↗

Upcoming milestones

2028-03 (ESTIMATED) · Phase 1/Phase 2 · Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease · NCT06189963
2028-04 (ESTIMATED) · Phase 2 · Open-Label Extension Protocol to SNK01-AD01 Study · NCT07228078

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

Jul 17, 2025 Partnership / licensing announced Jul 17, 2025. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 8

Record	Title	Phase	Status	Start	Primary completion
NCT06189963	Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease	Phase 1/Phase 2	Recruiting	Nov 21, 2023	2028-03 (estimated)
NCT07228078	Open-Label Extension Protocol to SNK01-AD01 Study	Phase 2	Recruiting	Jun 30, 2025	2028-04 (estimated)
NCT05990920	Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy	Phase 1	Completed	Aug 23, 2023	Apr 12, 2024 (actual)
NCT04678453	Safety of SNK01 in Subjects With Alzheimer's Disease (ASK-AD)	Phase 1	Terminated	Jan 6, 2021	Aug 16, 2023 (actual)
NCT05099549	Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers	Phase 1/Phase 2	Terminated	Nov 3, 2021	Sep 21, 2023 (actual)
NCT03941262	Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy	Phase 1	Completed	Jul 15, 2019	Feb 17, 2023 (actual)
NCT04464967	Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers	Phase 1/Phase 2	Withdrawn	2021-03	2022-08 (estimated)
NCT03894579	Autologous Natural Killer Cells in Subjects With Plaque Psoriasis	Phase 1	Completed	Jul 18, 2019	Dec 3, 2019 (actual)

Open jobs 1

Title	Location (from posting, not HQ)	Employer posted	First seen	Level
Analyst II	Santa Ana, CA, Santa Ana, CA, US	Sep 1, 2026	Oct 11, 2026	Mid

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Connect

See your connections at NKGEN Biotech on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18